Itaconix Plc (ITXXF) Q2 2025 Earnings Name Transcript

Operator

Good afternoon, and welcome to the Itaconix plc investor presentation. [Operator Instructions] The corporate will not be ready to reply each query acquired through the assembly itself. Nonetheless, the corporate can overview all questions submitted right now and publish responses the place it is acceptable to take action. Earlier than we start, I would prefer to submit the next ballot. And I would now like at hand you over to John Shaw, CEO. Good afternoon, sir.

John Shaw
Co-Founder, CEO & Director

Good afternoon. John Shaw, CEO of Itaconix, and welcome to our report on our interim outcomes for 2025. When it comes to our highlights, it is a vital half 12 months for us for the long-term improvement of Itaconix into a big, extremely worthwhile specialty components firm. Our H1 highlights are actually round our monetary ends in a few completely different areas. We recorded report revenues, report gross income, close to impartial adjusted EBITDA, and we nonetheless have loads of sources for added progress. On our industrial progress aspect, we made a significant step in the direction of reaching profitability from each the income progress aspect and the income base we have now in place for touchdown and increasing new clients.

Lastly, we’re additionally organising future progress with 2 main new initiatives that superior within the first half with each our SPARX program, our Bio*Asterix program. Our path to being a big specialty ingredient firm facilities across the worth and potential for itaconic acid. Itaconic acid is a pure molecule. It is a metabolite truly produced in our our bodies within the pure world by way of biochemistry. Its worth is derived from its distinctive mixture of three practical websites which can be yet one more than acrylic acid